Estrogen replacement therapy and tamoxifen are contra-indicated in patients with endometrial stromal sarcoma

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 414-

  Reichardt, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER RECURRENCE; ENDOMETRIUM SARCOMA; ESTROGEN THERAPY; HUMAN; HYSTERECTOMY; LETTER; MENOPAUSAL SYNDROME; METASTASIS; PRIORITY JOURNAL;

EID: 33746031057     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.03.024     Document Type: Letter

References (1)

1. Pink D., Lindner T., Mrozek A., Kretzschmar A., Thuss-Patience P.C., Dörken B., et al. Harm or benefit of hormonal treatment in metastatic low grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol (2005) [Electronic publication ahead of print]